company background image
OPNT

Opiant Pharmaceuticals NasdaqCM:OPNT Stock Report

Last Price

US$20.12

Market Cap

US$104.0m

7D

0.1%

1Y

-17.5%

Updated

29 Nov, 2022

Data

Company Financials +
OPNT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

OPNT Stock Overview

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose.

Opiant Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Opiant Pharmaceuticals
Historical stock prices
Current Share PriceUS$20.12
52 Week HighUS$37.71
52 Week LowUS$7.34
Beta0.51
1 Month Change107.17%
3 Month Change67.81%
1 Year Change-17.51%
3 Year Change41.89%
5 Year Change-34.87%
Change since IPO-83.23%

Recent News & Updates

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21
Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19
Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09
Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06
The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05
News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27
Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Shareholder Returns

OPNTUS PharmaceuticalsUS Market
7D0.1%0.5%-0.9%
1Y-17.5%13.0%-18.9%

Return vs Industry: OPNT underperformed the US Pharmaceuticals industry which returned 12.2% over the past year.

Return vs Market: OPNT exceeded the US Market which returned -20.5% over the past year.

Price Volatility

Is OPNT's price volatile compared to industry and market?
OPNT volatility
OPNT Average Weekly Movement32.4%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: OPNT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 32% a week.

Volatility Over Time: OPNT's weekly volatility has increased from 20% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200538Roger Crystalhttps://www.opiant.com

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

Opiant Pharmaceuticals, Inc. Fundamentals Summary

How do Opiant Pharmaceuticals's earnings and revenue compare to its market cap?
OPNT fundamental statistics
Market CapUS$103.98m
Earnings (TTM)-US$33.09m
Revenue (TTM)US$22.34m

4.7x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OPNT income statement (TTM)
RevenueUS$22.34m
Cost of RevenueUS$29.45m
Gross Profit-US$7.11m
Other ExpensesUS$25.97m
Earnings-US$33.09m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-6.40
Gross Margin-31.85%
Net Profit Margin-148.12%
Debt/Equity Ratio67.1%

How did OPNT perform over the long term?

See historical performance and comparison